

Immunogenicity of Zoster Vaccine in Allogeneic Hematopoietic Stem Cell Transplant Recipients

NCT05554068

Status	RECRUITING
Phase	Phase 2
Sponsor	Loyola University
Enrollment	100 participants

Key Eligibility Criteria

Inclusion (9)

- Age e18 years
 - e 12months and d 36 months post-AlloSCT
 - Donor sources: matched related, matched unrelated, cord blood
 - Any malignant hematological disease including acute leukemia, myelodysplastic syndrome, non-Hodgkin's lymphoma, Hodgkin's lymphoma, chronic lymphocytic leukemia, chronic myeloid leukemia, multiple myeloma, and myeloproliferative disorders.
 - Any conditioning regimen
- ... and 4 more (see full listing online)

Exclusion (7)

- Patients who had zoster after an allogeneic transplant and prior to enrollment
 - Patients who are currently pregnant
 - History of allergic reactions attributed to compounds of similar chemical or biologic composition to the recombinant zoster vaccine, Shingrix, or other agents used in study.
 - Patients who have had a relapse of their primary hematological disease
 - Previous allogeneic stem cell transplantation
- ... and 2 more (see full listing online)

Locations (1 total)

Loyola University Medical Center, Maywood, Illinois, United States